Office-Based Intralesional Steroid Injection for Treatment of Laryngeal Sarcoidosis
dc.contributor.author | Farlow, JL | |
dc.contributor.author | Park, JV | |
dc.contributor.author | Morrison, RJ | |
dc.contributor.author | Kupfer, RA | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-01-09T17:30:13Z | |
dc.date.available | 2024-01-09T17:30:13Z | |
dc.date.issued | 2021-08-01 | |
dc.identifier.issn | 0003-4894 | |
dc.identifier.issn | 1943-572X | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/33583192 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/191981 | en |
dc.description.abstract | Objectives: To report preliminary outcomes of a case series of in-office intralesional steroid injections for treatment of laryngeal sarcoidosis. Methods: After diagnosis of laryngeal sarcoidosis, 3 patients were offered in-office steroid injections for primary or adjunctive treatment. Triamcinolone 40 was injected into supraglottic sarcoidosis lesions in the office using a channel laryngoscope. Response to treatment and need for further injections was determined based on patient symptoms and repeat flexible laryngoscopy. Results: In-office intralesional steroid injections provided rapid symptom relief within days that lasted for months, thus decreasing the frequency of operative interventions. For one of the patients in this series, these injections even eliminated the need for tracheostomy. No complications were observed. Conclusions: In-office intralesional steroid injection is an emerging adjunctive treatment for laryngeal sarcoidosis. Prospective studies are required to determine efficacy and long-term risk profiles in relation to the current standard of operative management and systemic treatments. | |
dc.format.medium | Print-Electronic | |
dc.language | eng | |
dc.publisher | SAGE Publications | |
dc.subject | ambulatory surgical procedures | |
dc.subject | laryngoscopy | |
dc.subject | laryngostenosis | |
dc.subject | larynx | |
dc.subject | sarcoidosis | |
dc.subject | steroids | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Ambulatory Care | |
dc.subject | Female | |
dc.subject | Glucocorticoids | |
dc.subject | Humans | |
dc.subject | Injections, Intralesional | |
dc.subject | Laryngeal Diseases | |
dc.subject | Middle Aged | |
dc.subject | Sarcoidosis | |
dc.subject | Triamcinolone | |
dc.title | Office-Based Intralesional Steroid Injection for Treatment of Laryngeal Sarcoidosis | |
dc.type | Article | |
dc.identifier.pmid | 33583192 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/191981/2/2021_Oto-HNS_In Office Steroids for Sarcoidosis.pdf | |
dc.identifier.doi | 10.1177/0003489421995287 | |
dc.identifier.doi | https://dx.doi.org/10.7302/21982 | |
dc.identifier.source | Annals of Otology, Rhinology and Laryngology | |
dc.description.version | Published version | |
dc.date.updated | 2024-01-09T17:30:12Z | |
dc.identifier.orcid | 0000-0003-1214-4960 | |
dc.identifier.orcid | 0000-0002-2313-8542 | |
dc.identifier.orcid | 0009-0000-0757-8348 | |
dc.description.filedescription | Description of 2021_Oto-HNS_In Office Steroids for Sarcoidosis.pdf : Published version | |
dc.identifier.volume | 130 | |
dc.identifier.issue | 8 | |
dc.identifier.startpage | 976 | |
dc.identifier.endpage | 979 | |
dc.identifier.name-orcid | Farlow, JL; 0000-0003-1214-4960 | |
dc.identifier.name-orcid | Park, JV | |
dc.identifier.name-orcid | Morrison, RJ; 0000-0002-2313-8542 | |
dc.identifier.name-orcid | Kupfer, RA; 0009-0000-0757-8348 | |
dc.working.doi | 10.7302/21982 | en |
dc.owningcollname | Otolaryngology, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.